Partnerersättning i Q4 Bolagets licenspartner Tango Therapeutics har avancerat sitt projekt TNG348 i...
Bra tillväxt och goda marginaler y/y Arise rapporterade ett starkt resultat för Q4’23 med en försälj...
Utmanande år för Waystream 2023 blev ett utmanande år för Waystream.
Ökad vinst trots fortsatt motvind i fordonssegmentet Omsättningen under det fjärde kvartalet minskad...
Exel’s Q4 results continued to be very low mostly across the board.
Alisa Bank’s H2 results were quite in line with our estimates.
Solteq’s Q4 was as expected weak, earnings improvement in Utilities a positive.
H2 2023 net sales and EBIT missed our estimates, yet profitability was better than expected excl.
Raute’s Q4 profitability didn’t meet our estimates as Wood Processing still lacked volume while deve...
Starbreeze's year-end report for 2023 caused a stock drop of about 15%.
Sales -9% and company adj. EBITDA SEK -8.5m vs. ABGSCe Interest rate environment and mix effects wei...
Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently an...
Redeye updates on GiG following its Q4-results which came in close to our expectations.
Minor '24e-'25e EBITDA estimate changes We deem positive EBIT in '24 to be a credible target EV/ARR ...
Redeyes is only making minor changes to our forecasts following the Q4 report.
Redeye reduces its sales and profitability forecast following softer Q4-figures.
Sales +7% y-o-y, +1% vs. ABGSCe 12.7% adj. EBIT margin (vs.
Redeye states that the report aligned with preliminary figures and showed net sales in line with est...
Redeye believes 2024 could better demonstrate Sedana Medical’s European expansion and increase the c...
